CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6929 result(s)

Grey Matters: a practical tool for searching health-related grey literature

Last Updated: May 8, 2019
Result type: Resources

Now revised and updated, explore CADTH’s free online resource for grey literature searching, “Grey Matters: a practical tool for searching health-related grey literature.” Grey Matters: a practical tool for searching health-related grey literature

In order to use the tool: save file open file “Open as read only?” will appear ...

CADTH Announces New Vice-President, Pharmaceutical Reviews

Published on: May 6, 2015
Result type: News

We are pleased to announce the appointment of Brent Fraser to the position of Vice-President, Pharmaceutical Reviews, effective August 4, 2015. In this role, Brent will be responsible for the CADTH Common Drug Review, the pan-Canadian Oncology Drug Review, and all other aspects of CADTH work in the pharmaceutical space. Brent joins CADTH from t...

2017 CADTH Symposium

Event Date: April 23, 2017 - April 25, 2017
Result type: Events

The 2017 CADTH Symposium will feature another outstanding roster of Canadian and international experts, thought-provoking plenary sessions, educational workshops, and insightful panel, oral, and poster presentations. We’re coming back to Ottawa so you can also enjoy the history and pageantry of the year-long celebration of Canada’s 150th anniv...

2016 CADTH Symposium

Event Date: April 10, 2016 - April 12, 2016
Result type: Events

EVIDENCE FOR EVERYONE Expanding the Reach of Health Technology Assessment Initially established as a tool for policy-makers, health technology assessment (HTA) now supports a much broader range of decision-makers. Everyone — whether technology developers in academic settings and industry, patients, clinicians, regional health authority and hos...

Denosumab (Drug Plan Submission) (Xgeva)

Last Updated: September 7, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: Denosumab (Drug Plan Submission)
Indications: Prevention of skeletal-related events due to bone metastases from breast cancer

  • Brand Name: Xgeva
  • Manufacturer: Amgen Canada Inc.
  • Project Number: SR0433-000
  • Project Status: Complete
  • Submission Type: New

Frequently Asked Questions: Expanding the CADTH Drug Review Process to Receive Patient Input Submissions From Individual Patients and Caregivers

Published on: October 5, 2015
Result type: General Content

Who is eligible under the newly expanded process to submit patient input to the CADTH pan-Canadian Oncology Drug Review (pCODR) program as an individual patient or caregiver? pCODR will accept patient input from individual patients and caregivers when there is no patient advocacy group representing patients with the particular tumour for w...